AKASA vs CoverMyMeds

Side-by-side comparison of AI visibility scores, market position, and capabilities

AKASA logo

AKASA

ChallengerHealthcare

AI-Powered Revenue Cycle Management

AKASA is the leading generative AI platform for healthcare revenue cycle management; #1 RCM startup 2025 (Black Book); Cleveland Clinic strategic partnership; removes 71% of claims from staff queues.

About

AKASA is a healthcare technology company applying generative AI to automate and optimize revenue cycle management (RCM) for hospitals and health systems across the United States. Founded in 2018 and headquartered in San Francisco, AKASA's platform is trained on each health system's own clinical and financial data, enabling AI that understands the specific nuances of individual organizations' billing workflows, payer rules, and coding patterns. The company automates critical revenue cycle processes including prior authorization, medical coding, claim status retrieval, and denial management — reducing manual work, accelerating cash collections, and decreasing operational costs without requiring health systems to replace existing EHR or billing systems.

Full profile
CoverMyMeds logo

CoverMyMeds

LeaderHealthcare Revenue Cycle & Health IT

Prior Authorization & Medication Access

Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies;

AI VisibilityBeta
Overall Score
A90
Category Rank
#1 of 1
AI Consensus
84%
Trend
up
Per Platform
ChatGPT
98
Perplexity
97
Gemini
92

About

CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.

Full profile

Key Details

Category
AI-Powered Revenue Cycle Management
Prior Authorization & Medication Access
Tier
Challenger
Leader
Entity Type
brand
product

Capabilities & Ecosystem

Capabilities

Only CoverMyMeds
Prior Authorization & Medication Access
CoverMyMeds is classified as product (part of McKesson).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.